Lee Greenberger on Newly Approved Drugs for Multiple Myeloma

Article

Lee Greenberger, PhD, chief scientific officer, The Leukemia & Lymphoma Society, discusses new agents that were recently approved for multiple myeloma.

Lee Greenberger, PhD, chief scientific officer, The Leukemia & Lymphoma Society, discusses new agents that were recently approved for multiple myeloma.

Three drugs were FDA approved within 3 weeks — Darzalex (daratumumab), Ninlaro (ixazomib), and Empliciti (elotuzumab). Darzalex and Empliciti are antibodies, and Ninlaro is a proteasome inhibitor.

The agents can be used as monotherapy or in combination with conventional therapy, Greenberger explains. They have also extended progression-free survival in patients with myeloma.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Photo of a woman with brown hair and bangs, surrounded by a blue border
Photo of an open bottle of pills
4 experts in this video
4 experts in this video
Photo of a woman wearing a blazer and a colorful scarf in front of a blue background
Related Content
Graphic of a seal that reads "FDA Approved"

July FDA Oncology Approvals Include Options for NSCLC, Myeloma, and More

Bridget Hoyt
August 2nd 2025
Article

New FDA approvals in July include therapies for NSCLC, relapsed multiple myeloma, liver cancer, and B-cell malignancies.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
August 2nd 2025
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Graphic of a person with lung tumors

Q&A: Nursing Considerations From Immune Cell Effector Therapy Experts

Bridget Hoyt
August 2nd 2025
Article

2025 ICE-T Conference presenters explain what nurses and APPs should take into account as immune cell effector therapies become more widely used.

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Lindsay Fischer
August 2nd 2025
Podcast

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

Photo of a main holding his lower back in pain with a graphic of a kidney overlaying

Opinion: IV Magnesium May Help Prevent Cisplatin-Induced AKI

Amanda Brink, DNP, APRN, FNP-BC, AOCNP
August 2nd 2025
Article

Oncology nurses can assess patients’ risk factors and advocate for preventive strategies that protect kidney function during cisplatin therapy.

Photo of a woman with brown hair and bangs, surrounded by a blue border

AE Education Aids Breast Cancer Decisions, Says Survivorship Expert

Michelle Kirschner, RN, MSN, ACNP, APRN-BC
August 2nd 2025
Article

Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.